An2 Therapeutics, INC 8-K filings

AN2 Therapeutics reported Q2 2026 results, detailing progress in Phase 2 trials for polycythemia vera and Chagas disease, alongside pipeline expansion and increased R&D spending.

AN2 Therapeutics announced positive results from studies of its oral drug AN2-502998 for chronic Chagas disease, showing 100% parasite elimination in nonhuman primates and a favorable safety profile in human trials.

AN2 Therapeutics reported Q1 2026 results, highlighting progress in its oral epetraborole programs for polycythemia vera and M. abscessus lung disease, alongside a new ENPP1 candidate for solid tumors, while maintaining a projected cash runway into 2029.

AN2 Therapeutics has entered into an Open Market Sale Agreement with Jefferies LLC to sell up to $80 million of its common stock.

AN2 Therapeutics, Inc. has repriced all outstanding stock options granted prior to March 19, 2026, to $3.91 per share to enhance retention and motivation.

AN2 Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting pipeline advancements and a private placement extending its cash runway into 2029.

AN2 Therapeutics, Inc. announced the appointment of Sarah Williams as Vice President, Controller, and Principal Accounting Officer, effective February 1, 2026, alongside a revised compensation structure for CFO Lucy Day.

AN2 Therapeutics reported third quarter 2025 financial results, highlighting progress in its Chagas disease, oncology, and infectious disease programs, and extended its cash runway into 2028.

AN2 Therapeutics reported Q2 2025 financial results, highlighting pipeline advancements and a projected cash runway into 2028.

AN2 Therapeutics, Inc. has entered into exchange agreements with Coastlands Capital Partners LP, converting 2.8 million shares of common stock into pre-funded warrants to manage beneficial ownership.

AN2 Therapeutics, Inc. has posted an updated investor presentation highlighting its clinical-stage boron chemistry platform, strong cash position, and progress across its Chagas disease, Melioidosis, and emerging oncology programs.

AN2 Therapeutics, Inc. announced the successful election of three Class III directors and the ratification of PricewaterhouseCoopers LLP as its independent auditor at its 2025 annual meeting of stockholders.

AN2 Therapeutics announces its Q1 2025 financial results, reporting a net loss of $10.6 million and a cash runway extending into 2028, while also highlighting advancements in its clinical programs for Chagas disease and melioidosis.

AN2 Therapeutics' Phase 3 trial for EBO-301 in MAC lung disease failed to meet its primary endpoint, leading the company to prioritize its boron chemistry pipeline and other clinical programs.

AN2 Therapeutics reports its Q4 and full year 2024 financial results, highlighting progress in its clinical programs and a cash runway extending through 2027.

AN2 Therapeutics announced positive clinical data from its EBO-301 trial and a 50% reduction in expenditures, extending its cash runway through 2027.

AN2 Therapeutics has appointed Joshua Eizen, previously Chief Legal Counsel, as Chief Legal Officer and Chief Operating Officer, effective immediately.

AN2 Therapeutics adopts a limited-duration stockholder rights plan to protect against potential hostile takeovers and ensure fair treatment of all shareholders.

AN2 Therapeutics reported its Q2 2024 financial results, highlighted by a $104.5 million cash position and a shift in focus to its internal boron chemistry platform after terminating a Phase 2/3 trial.

AN2 Therapeutics discontinues its EBO-301 study for MAC lung disease, resulting in a workforce reduction and strategic shift towards its boron chemistry platform.

AN2 Therapeutics held its 2024 annual meeting, electing three Class II directors and approving amendments to the company's certificate of incorporation.

AN2 Therapeutics announced its first quarter 2024 financial results and provided an update on its Phase 2/3 clinical trial for epetraborole, including a planned topline data release in August 2024.

AN2 Therapeutics announced its fourth quarter and full year 2023 financial results, along with updates on its clinical programs, including a pause in Phase 3 enrollment for its lead drug candidate, epetraborole.

AN2 Therapeutics has voluntarily paused enrollment in its Phase 3 clinical trial for epetraborole due to potentially lower than expected efficacy observed in a blinded analysis of the Phase 2 study.